Experimental vaccine strategies for cancer immunotherapy

Journal of Biomedical Science

Volumn 5, Issue 4, 1998, Pages 231-252

  Chen, Chien Hung ^a,b   Wu, T C ^b,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen; Cancer; Cytotoxic T lymphocyte; Dendritic cell; Immunotherapy; Tumor immunology; Vaccine

Indexed keywords

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELLULAR IMMUNITY; HUMAN; IMMUNOSTIMULATION; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0031875403     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/BF02255855     Document Type: Review

References (185)

1. Aicher A, Westemann J, Cayeux S, Willimsky G, Daemen K, Blankenstein T, Uckert W, Dorken B, Pezzutto A. Successful retroviral mediated transduction of a reporter gene in human dendritic cells: Feasibility of therapy with gene-modified antigen presenting cells. Exp Hematol 25:39-44; 1997.
2. Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J, Kantor JA. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MTJC1 gene and the murine T-cell costimulatory molecule B7. J Immunother 20:38-47;1997.
3. Armstrong TD, Clements VK, Martin BK, Ting JPY. Ostrand-Rosenberg S. Major histocompatibihty complex class H-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 94:6886-6891;1997.
4. Arthur JF, Butterfield LH, Roth MD, Bui LA, Kiertscher SM, Lau R, Dubinett S, Glaspy J, McBride WH, Economou JS. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 4:17-25;1997.
5. Aruga A, Aruga E, Chang AE: Reduced efficacy of auogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant. Cancer Res 57:3230-3237;1997.
6. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186: 1177-1182;1997.
7. Austyn JM. New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med 183:1287-1292;1996.
8. Bello-Fernandez C, Matyash M, Strobl H, Pickl WF, Majdic O, Lyman SD, Knapp W. Efficient retrovirus-mediated gene transfer of dendritic cells generated from CD34+ cord blood cells under serum-free conditions. Hum Gene Ther 8:1651-1658;1997.
9. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 196:121-135;1996.
10. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465-472;1996.
11. Borysiewicz LK, Fiander A, Nimako M. Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME, Rutherford E, Hickling JK, Inglis SC. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as irnmunotherapy for cervical cancer. Lancet 347: 1523-1527;1996.
12. Bramson JL, Hitt M, Addison CL, Mulier WJ, Bauldie J, Graham FL. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 7:1995-2002;1996.
13. Bramson JL, Hitt M, Gauldie J, Graham FL. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 4: 1069-1076;1997.
14. Breel M, Laman J, Kraal G. Murine hybrid cell lines expressing the NLDC-145 dendritic cell determinant. Immunobiology 178:167-176; 1988.
15. Bright RK, Beames B, Shearer MH, Kennedy RC. Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA encoding SV40 large tumor antigen. Cancer Res 56:1126-1130;1996.
16. Bronte V, Carroll MW, Goletz TJ, Wang M, Overwijk WW, Marincola F, Rosenberg SA, Moss B, Restifo NP. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci USA 94: 3183-3188;1997.
17. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. Immunol 158:3270-3276;1997.
18. Broxmeyer HE, Lu L, Cooper S, Ruggieri L, Li ZH, Lyman SD. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp Hematol 23:1121-1129;1995.
19. Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, Woo SL, Chen SH. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 93:11302-11306;1996.
20. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360:258-261;1992.
21. Caux C, Vanbervliet B, Massacner C, Dezutter-Dambuyant C, de Saint-Vis B, Jacquet C, Yoneda K, Imamaura S, Schmitt D, Banchereau J. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med 184:695-706;1996.
22. Cella M, Engenng A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendntic cells. Nature 388:782-787;1997.
23. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 9:10-16; 1997.
24. Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA, Restifo NP Costimulation enhances the active immunotherapy effect of recombmani anticancer vaccines. Cancer Res 56: 2832-2836;1996.
25. Chen K, Braun S, Lyman S, Fan Y, Traycoff CM, Wiebke EA, Gaddy J, Sledge G, Broxmever HE, Cornetta K. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res 57:3511-3516;1997.
26. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093-1102;1992.
27. Chen L, Chen D, Block E, O'Donnell M, Kufe DW, Clinton SK. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol 159:351-359;1997.
28. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 156:224-231;1996.
29. Chen TT, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 153:4775-4787;1994.
30. Chow YH, Chiang BL, Lee YL, Chi WK, Lin WC, Chen YT, Tao MH. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulased by codelivery of various cytokine genes. J Immunol 160:1320-1329; 1998.
31. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J ExpMed 186:1623-1631;1997.
32. Ciernik IF, Berzofsky JA, Carbone DP. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 156:2369-2375; 1996.
33. Collins DS, Findlay K, Harding CV. Processing of exogenous liposome-encapsulated antigens in vivo generates class I MHC-restricted T cell responses. J Immunol 148:3336-3341; 1992.
34. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2:1122-1128;1996.
35. Conry RM, LoBuglio AF, Loechel F, Moore SE. Sumerel LA, Barlow DL, Curiel DT. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther 2: 59-65;1995.
36. Corr M, Tighe H, Lee D, Dudler J, Trieu M, Brinson DC, Carson DA. Costimulation provided by DNA immunization enhances antitumor immunity. J Immunol 159:4999-5004; 1997.
37. Coveney E, Wheatley GH 3rd, Lyerliy HK. Active immunization using dendntic cells mixed with jumor cells inhibits the growth of primary breast cancer. Surgery 122:228-234; 1997.
38. Darji A, Guzman CA, Gerstel B, Wachholz P, Timmis KN, Wehland J, Chakraborty T, Weiss S. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91:765-775; 1997.
39. Das Gupta TK, Cohen EP, Richards JM. Phase I evaluation of interleukin-2-transfected irradiated allogeneic melanoma for the treatment of metastatic melanoma: Appendix 1: Protocol. Hum Gene Ther 8:1701-1714;1997.
40. De Bruijn MLH, Schuurhuis DH, Vierboom MPM. Vermeiden H, de Cock KAJ, Ooms ME, Ressing ME, Toebes M, Franken KL, Drijfhout JW, Ottenhoff THM, Offringa R, Melief CJM. Immunization with human papillomavirus type 16 (HPV 16)oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV 16-induced tumor cells. Cancer Res 58:724-731; 1998.
41. Deres K, Schild H, Wiesmuller KH, Jung G, Rammensee HG. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342:561-564; 1989.
42. Descamps V, Duffour MT, Mathieu MC, Fernandez N, Cordier L, Abina MA, Kremer E, Perricaudet M, Haddada H. Strategies for cancer gene therapy using adenoviral vectors. J Mol Med 74:183-189;1996.
43. Dietz AB, Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 91:392-398;1998.
44. Dilloo D, Brown M, Roskrow M, Zhong W, Holladay M, Holden W, Brenner M. CD40 ligand induces an antileukemia immune response in vivo. Blood 90:1927-1933;1997.
45. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 15:617-648;1997.
46. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543;1993.
47. Dranoff G, Soiffer R, Lynch T, Mihm M, Jung K, Kolesar K, Liebster L, Lam P, Duda R, Mentzer S, Singer S, Tanabe JC, Johnson R, Sober A, Bhan A, Clift S, Cohen L, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Mulligan RC. A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther 8:111-123;1997.
48. Esche C, Subbotin V, Maliszewski C, Lotze M, Shurin M. Flt3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 58:380-383;1998.
49. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegger J, Melief CJ, Kast WM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23:2242-2249;1993.
50. Geissler M, Wands G, Gesien A, de La Monte S, Bellet D, Wands JR. Genetic immunization with the free human chorionic gonadotropin beta subunit elicits cytotoxic T lymphocyte responses and protects against tumor formation in mice. Lab Invest 76:859-871;1997.
51. Germain RN. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation (review). Cell 76:287-299;1994.
52. Golumbek PT, Azhari R, Jaflee EM, Levitsky HI, Lazenby A, Leong K, Pardoll DM. Controlled release, biodegradable cytokine depots: A new approach in cancer vaccine design. Cancer Res 53:5841-5844;1993.
53. Gonczol E, Berensci K, Pincus S, Endresz V, Meric C, Paoletti E, Plotkin SA. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotem B vaccine candidate. Vaccine 13:1080-1085;1995.
54. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3:558-561;1997.
55. Greenstone HL, Nieland JD, de Visser KE, De Bruijn MLH, Kimbauer R, Roden RBS, Lowy DR, Kast WM, Schiller JT. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotien in an HPV16 tumor model. Proc Natl Acad Sci USA 95:1800-1805;1998.
56. Grewal IS, Borrow P, Pamer EG, Oldstone MB, Flavell RA. The CD40-CD154 system in anti-infective host defense. Curr Opin Immunol 9:491-497;1997.
57. Grossmann ME, Brown MP, Brenner MK. Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther 8: 1935-1943;1997.
58. Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J, Sy MS. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 263:518-520;1994.
59. Guo YJ, Che XY, Shen F, Xie TP, Ma J, Wang XN, Wu SG, Anthony DD, Wu MC. Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat Med 3:451-455;1997.
60. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, Kastelein R, Hudak S, Wagner J, Mattson J. et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 368:643-648;1994.
61. Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol 153:4925-4933;1994.
62. Hariharan K, Braslawsky G, Black A, Raychaudhuri S, Hanna N. The induction of cytotoxic T cells and tumor regression by soluble antigen formulation. Cancer Res 55:3486-3489;1995.
63. Hart DN. Dendritic cells: Unique leukocyte populations which control the primary immune response (review). Blood 90:3245-3487; 1997.
64. Herbst B, Kohler G, Mackensen A, Veelken H, Kulmburg P, Rosenthal FM, Schaefer HE, Mertelsmann R, Fisch P, Lindenmann A. In vitro differentiation of CD34+ hemaiopoietic progenitor cells toward distinct dendritic cell subsets of the Birbeck granule and MIIC-positive Langerhans cell and the interdigitating dendritic cell type. Blood 88:2541-2548;1996.
65. Heufler C, Koch F, Schuler G. Granulocyte/ macrophage colony-stimulating factor and interleukin I mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med 167: 700-705;1988.
66. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52-58;1996.
67. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class Irestricted tumor antigens. Science 264:961-965;1994.
68. Huang H, Chen SH, Kosai K, Finegold MJ, Woo SL. Gene therapy for hepatocellular carcinoma: Long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo. Gene Ther 3:980-987; 1996.
69. Hwu P, Yang JC, Cowherd R, Reisman J, Shafer GE, Eshhar Z, Rosenberg SA. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55: 3369-3373;1995.
70. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693-1702; 1992.
71. Inaba K, Steinman RM, Pack MW, Aya H, Inaba M, Sudo T, Wolpe S, Schuler G. Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 175:1157-1167; 1992.
72. Irvine KR, Chamberlan RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 89:1595-1601; 1997.
73. Irvine KR, Rao JB, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156:238-245; 1996.
74. Jacobsen SE, Veiby OP. Myklebust J, Okkenhaug C, Lyman SD. Ability of flt3 ligand to stimulate the in vitro growth of primitive murine hematopoietic progenitors is potently and directly inhibited by transforming growth factor-beta and tumor necrosis factor-alpha. Blood 87:5016-5026;1996.
75. Jaffee EM, Pardoll DM. Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods 12:143-153;1997.
76. Jondal M, Schirmbeck R, Reimann J. MHC class I-restricted CTL responses 10 exogenous antigens (review). Immunity 5:295-302;1996.
77. Karpoff HM, D'Angelica M, Blair S, Brownlee MD, Federoff H, Fong Y. Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon. J Clin Invest 99:799-804;1997.
78. Kay MA, Liu D, Hoogerbrugge PM. Gene therapy. Proc Natl Acad Sci USA 94:12744-12746; 1997.
79. Kim CJ, Prevette T, Cormier J, Overwijk W, Roden M, Restifo NP, Rosenberg SA, Marincola FM. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J Immunother 20:276-286;1997.
80. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 90:4942-4946;1993.
81. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldbaus AL, Greenberg NM, Burg MB, Allison JP. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 94: 8099-8103;1997.
82. Langer R, Cima LG, Tamada JA, Wintermantel E. Future directions in biomaterials. Biomaterials 11:738-745;1990.
83. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736;1996.
84. Li Z. Priming of T cells by heat shock protein-peptide complexes as the basis of tumor vaccines. Semin Immunol 9:315-322;1997.
85. Lin KY, Guamieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21-26;1996.
86. Lotze MT, Rubin JT, Carty S, Edington H, Ferson P, Landreneau R, Pippin B, Posner M, Rosenfelder D, Watson C. et al. Gene therapy of cancer A pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum Gene Ther 5: 41-55;1994.
87. Lyman SD. Biology of flt3 ligand and receptor (review). Int J Hematol 62:63-73;1995.
88. Lyman SD, Jacobsen SEW. c-kit ligand and FH3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities. Blood 91: 1101-1134;1998.
89. Lyman SD, James L, Escobar S, Downey H, de Vries P, Brasel K, Stocking K, Beckmann MP, Copeland NG, Cleveland LS, et al. Identification of soluble and membrane-bound isoforms of the munne flt3 ligand generated by alternative splicing of mRNAs. Oncogene 10:149-157;1995.
90. Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor A proliferative factor for primitive hematopoietic cells. Cell 75: 1157-1167;1993.
91. Lynch DH, Andreasen A, Maraskovsky E, Whitroore J, Miller RE, Schuh JC. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3:625-631; 1997.
92. Mahvi DM, Sondel PM, Yang NS, Albertini MR, Schiller JH, Hank J, Heiner J, Gan J, Swain W, Logrono R. Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma. Hum Gene Ther 8:875-891;1997.
93. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J Exp Med 184:1953-1962; 1996.
94. Marchand M, Weynants P, Rankin E, Arienti F. Belli F, Panniani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 (letter). Int J Cancer 63:883-885; 1995.
95. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 65: 1143-1152;1991.
96. Mayordomo JI, Zorina T, Storkus WJ, Zitvogei L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides ehcit protective and therapeutic antitumour immunity. Nat Med 1: 1297-1302;1995.
97. Mayordomo JI, Zonna T, Storkus WJ, Zitvogel L, Garcia-Prats MD, DeLeo AB, Lotze MT. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines (review). Stem Cells 15: 94-103;1997.
98. McAneny D, Ryan CA, Beazley RM, Kaufman HL. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol 3: 495-500;1996.
99. Melief CJ, Offringa R, Toes RE. Kast WM. Peptide-based cancer vaccines (review). Curr Opin Immunol 8:651-657;1996.
100. Minev BR, McFarland BJ, Spiess PJ, Rosenberg SA, Restifo NP. Insenion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res 54:4155-4161;1994.
101. Morse MA, Zhou LJ, Tedder TF, Lyerly HK, Smith C. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocvte-macrophage-colony-stimulating factor, imerleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy. Ann Surg 226:6-16;1997.
102. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93: 11541-11348;1996.
103. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29:371-380;1996.
104. Nair SK, Boczkowski D, Snyder D, Gilboa E. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J immunol 27:589-597; 1997.
105. Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 70:706-715;1997.
106. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332;1998.
107. Ostrand-Rosenberg S, Baskar S, Patterson N, Clements VK. Expression of MHC class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens 47:414-421;1996.
108. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317-322;1996.
109. Paglia P, Girolomoni G, Robbiati F, Granucci F, Ricciardi-Castagnoli P. Immortalized dendritic cell line fully competent in antigen presentation initiates primary T cell responses in vivo. J Exp Med 178:1893-1901; 1993.
110. Pan ZK, Ikonomidis G, Lazenby A, Pardoll D, Paterson Y. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat Med 1:471-477;1995.
111. Pan ZK, Ikonomidis G, Pardoli D, Paterson Y. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocylogenes vaccine. Cancer Res 55:5776-4779;1995.
112. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399-415; 1995.
113. Peng S, Frazer IH, Fernando GJ, Zhou J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 240:147-157;1998.
114. Petti tDK, Lawter JR, Huang WJ, Pankey SC, Nightlinger NS, Lynch DH, Schuh JA, Morrissey PJ, Gombotz WR. Characterization of poly(glycolide-co-D,L-lactide)/poly(D,L-lactide) microspheres for controlled release of GM-CSF, Pharm Res 14:1422-1430;1997.
115. Pierre P, Tudey SJ, Gatti E, Hull M, Meltzer J, Mirza A, Inaba K, Steinman RM, Mellman I. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388:787-792;1997.
116. Plotkin SA, Cadoz M, Meignier B, Meric C, Leroy O, Excler JL, Tartaglia J, Paoletti E, Gonczol E, Chappuis G. The safety and use of canarypox vectored vaccines. Dev Biol Stand 84:165-170;1995.
117. Putzer BM, Hitt M, Muller WJ, Emtage P, Gauldie J, Graham FL. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci USA 94:10889-10894;1997.
118. Rakhmilevich AL, Janssen K, Turner J, Gulp J, Yang NS. Cytokine gene therapy of cancer using gene gun technology: Superior antitumor activity of interleukin-12. Hum Gene Ther 8:1303-1311;1997.
119. Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine KR, Moss B, Rosenberg SA, Restifo NP. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: Enhancement by simultaneous B7-1 expression. J Immunol 156:3357-3365;1996.
120. Raychaudhuri S, Tonks M, Carbone F, Ryskamp T, Morrow WJ, Hanna N. Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo. Proc Natl Acad Sci USA 89:8308-8312;1992.
121. Reeves ME, Royal RE, Lam JS, Rosenberg SA, Hwu P, Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 56:5672-5677; 1996.
122. Restifo NP. The new vaccines: Building viruses that elicit antitumor immunity. Curr Opin Immunol 8:658-663;1996.
123. Ribas A, Butterfield LH, McBride WH, Jilani SM, Bui LA, Vollmer CM, Lau R, Dissette VB, Hu B, Chen AY, Glaspy JA, Economou JS. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenvirus-transduced murine dendritic ceus. Cancer Res 57:2865-2869;1997.
124. Robinson HL, Torres CA. DNA vaccines. Semin Immunol 9:271-283;1997.
125. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 3: 849-854;1997.
126. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G. Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83-93;1994.
127. Rosato A, Zambon A, Milan G, Ciminale V, D'Agostino DM, Macino B, Zanovello P, Collavo D. CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. Hum Gene Ther 8:1451-1458; 1997.
128. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE, Experience with the use of high-dose interleukic-2 in the treatment of 652 cancer patients. Ann Surg 210:474-484;discussion 484-485: 1989.
129. Roseaberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327;1998.
130. Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D. Murine Flt3, a gene encoding a novel lyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene 6:1641-1650;1991.
131. Rouse RJ, Nair SK, Lydy SL, Bowen JC, Rouse BT. Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. J Virol 68:5685-5689;1994.
132. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109-1118;1994.
133. Schirmbeck R, Bohm W, Melber K, Reimann J. Processing of exogenous heat-aggregated (denatured) and paniculate (native) hepatitis B surface antigen for class I-restricted epitope presentation. J Immunol 155:4676-4684; 1995.
134. Schirmbeck R, Bohm W, Reimann J. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that rejects syngeneic tumors. J Immunol 157:3550-3558;1996.
135. Schmidt W, Buschle M, Zauner W, Kirlappos H, Mechtler K, Trska B, Birnstiel ML. Cellfree tumor antigen peptide-based cancer vaccines. Proc Natl Acad Sci USA 94:3262-3267;1997
136. Scott AM, Weft S. Antibody-based immunological therapies. Curr Opin Immunol 9:717-722;1997.
137. Shawler DL, Dorigo O, Gjerset RA, Royston I, Sobol RE, Fakhrai H. Comparison of gene therapy with interleukin-2 gene modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma. J Immunother Emphasis Tumor Immunol 17:201-208;1995.
138. Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II moiecules. J Immunol 158:2723-2730;1997.
139. Shurin MR, Pandharipande PP, Zorina TD, Haluszcrak C, Subbotin VM, Hunter O, Brumfield A, Storkus WJ, Maraskovsky E, Lotze MT. FLT3 ligand induces the generation of functionally active dendritic cells in mice Cell Immunol 179:174-184;1997.
140. Siena S, Di Nicola M, Bregni M, Mortarini R, Anichini A, Lombardi L, Ravagnani F, Parmiaai G, Gianni AM. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol 23:1463-1471;1995.
141. Simons JW, Jaffe EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, Hauda KM, Beck LA, Leiferman KM, Owens AH Jr, Piantadosi S, Dranoff G, Mulligan RC, Pardoll DM, Marshall FF. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57:1537-1546;1997.
142. Song W, Kong HL, Carpenter H, Toni H, Granslein R, Rafii S, Moore MA, Crystal RG. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 186: 1247-1256;1997.
143. Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA, Hwu P. Dendntic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 186:1213-1221;1997.
144. Srivastava PK. Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens (review). Methods 12:165-171;1997.
145. Steinman RM. The dendritic cell system and its role in immunogenicity (review). Annu Rev Immunol 9:271-296;1991.
146. Storkus WJ, Zeh HJd, Salter RD, Lotze MT. Identification of T-cell epitopes: Rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother 14: 94-103;1993.
147. Strobl H, Bello-Fernandez C, Riedl E, Pickl WF, Majdic O, Lyman SD, Knapp W. flt3 ligand in cooperation with transforming growth factor-beta 1 potentiates in vitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions. Blood 90:1425-1434;1997.
148. Strobl H, Riedl E, Scheinecker C, Bello-Fernandez C, Pickl WF, Rappersberger K, Majdic O, Knapp W. TGF-beta 1 promotes in vitro development of dendritic cells from CD34+ hemopoietic progenitors. 3 Immunol 157:1499-1507;1996.
149. Strobl H, Riedl E, Scheinecker C, Bello-Fernandez C, Pickl WF, Rappersberger K, Majdic O, Knapp W. TGF-beta 1 promotes in vitro development of dendritic cells from CD34+ hemopoietic progenitors. J Immunol 157:1499-1507;1996.
150. Strunk D, Rappersberger K, Egger C, Strobl H, Kromer E, Elbe A, Maurer D, Stingl G. Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood 87:1292-1302; 1996.
151. Sun WH, Burkholder JK, Sun J, Gulp J, Turner J, Lu XG, Pugh TD, Ershler WB, Yang NS. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Natl Acad Sci USA 92:2889-2893;1995.
152. Suzue K, Zhou X, Eisen HN, Young RA, Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc Natl Acad Sci USA 94:13146-13151; 1997.
153. Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 2:1038-1041;1996.
154. Szabolcs P, Gallardo HF, Ciocon DH, Sadelain M, Young JW. Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. Blood 90:2160-2167;1997.
155. Szabolcs P, Moore MA, Young JW. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J Immunol 154:5851-5861;1995.
156. Sznol M, Holmlund J. Antigen-specific agents in development (review). Semin Oncol 24: 173-186;1997.
157. Tahara H, Zeh HJr, Storkus WJ, Pappo I, Watkins SC, Gubler U, Wolf SF, Robbins PD, Lotze MT. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54:182-189;1994.
158. Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 344:873-875;1990.
159. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117-120;1997.
160. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755-758;1993.
161. Tighe H, Corr M, Roman M, Raz E. Gene vaccination: Plasmid DNA is more than just a blueprint. Immunol Today 19:89-97;1998.
162. Tjoa BA, Enckson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Boynton AL, Murphy GP. Follow-up evaluation of prostate cancer patients infused with autologous dendntic cells pulsed with PSMA peptides. Prostate 32:272-278;1997.
163. Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability 10 reject tumors. J Immunol 156:3911-3918;1996.
164. Toes RE, Blom RJ, van der Voort E, Offringa R, Melief CJ, Kast WM. Protective antitumor immunity induced by immunization with completely allogeneic rumor cells. Cancer Res 56:3782-3787;1996.
165. Toes RE, Hoeben RC, van der Voort EIH, Ressing ME. van der Eb AJ, Melief CJM, Offringa R. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci USA 94:14660-14665;1997.
166. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 93:7855-7860;1996.
167. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259: 368-370;1993.
168. Tuting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or 'self antigens induce antitumor immunity in vivo. Eur J Immunol 27:2702-2707;1997.
169. Tuting T, Gambotto A, Baar J, Davis ID, Storkus WJ, Zavodny PJ, Narula S, Tahara H, Robbins PD, Lotze MT. Interferon-alpha gene therapy for cancer: Retro v irai transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Ther 4:1053-1060;1997.
170. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 9:684-693;1997.
171. van Kooten C, Banchereau J. Functional role of CD40 and its ligand (review). Int Arch Allergy Immunol 113:393-399;1997.
172. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405-413;1994.
173. Wan Y, Bramson J, Carter R, Graham F, Gauldie J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 8:1355-1363;1997.
174. Wang G, Chopra RK, Royal RE, Yang JC, Rosenberg SA, Hwu P. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nat Med 4:168-172;1998.
175. Wamier G, Duffour MT, Uyttenhove C, Gajewski TF, Lurquin C, Haddada H, Perricaudet M, Boon T. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int J Cancer 67:303-310;1996.
176. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 94:10833-10837;1997.
177. Witmer-Pack MD, Olivier W, Valinsky J, Schuler G, Stemman RM. Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med 166:1484-1498;1987.
178. Wu JY, Gardner BH, Kushner NN, Pozzi LA, Kensil CR, Cloutier PA, Coughlin RT, Newman MJ. Accessory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes. Cell Immunol 154:393-406;1994.
179. Wu TC, Guarnieri FG, Staveley OCKF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoil DM. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 92:11671-11675; 1995.
180. Yang S, Darrow TL, Vervaert CE, Seigier HF. Iminunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. Cell Immunol 179:84-95;1997.
181. Yang YF, Zou JP, Mu J, Wijesuriya R, Ono S, Walunas T, Bluestone J, Fujiwara H, Hamaoka T. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages. Cancer Res 57:4036-4041;1997.
182. York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14: 369-396;1996.
183. Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, Couture LA, Smith AE, Rosenberg SA. Antigen-specific tumor vaccines. Development and characterization of recombinant adeaoviruses encoding MARTI or gp100 for cancer therapy. J Immunol 156:700-710;1996.
184. Zhou LJ. Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 93:2588-2592;1996.
185. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87-97;1996.